Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating.
Mohamad HamiehJorge Mansilla-SotoIsabelle RivièreMichel SadelainPublished in: Cancer discovery (2023)
Improving the clinical efficacy of CAR T cell therapies will require engineering T cells that overcome heterogeneous and low-abundance target expression while minimizing reactivity to normal tissues. Recent advances in CAR design and logic gating are poised to extend the success of CAR T cell therapies beyond B-cell malignancies.